Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00035061
NCT00035061
Completed
Phase 2

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

Eli Lilly and Company0 sitesStarted: May 3, 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsUrologic NeoplasmsMetastases, Neoplasm
Drugspemetrexed

Overview

Phase
Phase 2
Status
Completed
OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

Study Design

Study Type
Interventional
Primary Purpose
Treatment

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.
  • •You must have at least one tumor that can be physically measured or scanned by x-ray.
  • •You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.

Exclusion Criteria

  • •You may not have used an experimental medicine or device within the past month.
  • •Cancer that has spread to your brain.
  • •If you are unwilling or unable to take folic acid or vitamin B12 supplements.

Investigators

Sponsor Class
Industry

Similar Trials

Completed
Phase 2
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumUrologic Neoplasms
NCT00034593Eli Lilly and Company
Completed
Phase 2
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or AbdomenNon-small Cell Lung CancerMesotheliomaLung Neoplasms
NCT00316225Eli Lilly and Company31
Completed
Phase 2
Pemetrexed as the First Treatment in Advanced or Metastatic Breast CancerBreast CancerBreast Neoplasms, MaleCarcinoma, Ductal
NCT00106002Eli Lilly and Company37
Terminated
Phase 2
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder CancerUrinary Bladder Neoplasms
NCT02560038The University of Texas Health Science Center, Houston3
Completed
Phase 2
A Trial for Patients With Advanced/Recurrent Cervical CancerCervical Intraepithelial NeoplasiaUterine NeoplasmsGenital Neoplasms, Female
NCT00190983Eli Lilly and Company29